In August, finally I sold all my Matrix shares after holding them for almost 7 years. The move came amid criticism that the exchange is allowing many companies with limited growth prospects and weak governance standards to remain listed on the main board, which many argue is holding back gains in the Topix index. After plunging to $9.08, FAS came back and traded above $9.30 and then broke back above $10. If its share price drop, then probably it’s not good, and vice versa. Mark Meadows, the White House chief of staff, and Larry Kudlow, director of the National Economic Council, then hit back at Democrats for failing to seek a compromise in the talks. Chipotle (CMG) – Chipotle (CMG) exploded back above $450 this week. China 3x Bull ETF (YINN) – YINN is pulling back with the boutiques market after hitting a new 52 week high this week. It might drop back to the ground if it can’t grow its business and deliver consistent profit.
Krono’s share price makes some progress but I read somewhere that its business model is not that good. Frankly I don’t understand fully all those exercises and I’m also lazy to read all of them. When I bought BAuto in Oct15, it was for its growth potential, not its dividends. I actually “hoped” for this to happen when I bought this super penny warrants in Nov20. As for MyNews, its share price in Nov20 fell below the worst moment in Mac20. So, I used my system of insider analysis and company analysis to single out my favorites in the worst hit sectors. The strategy in Genetec is similar to Geshen, a loss-making company which has a potential to turnaround. I added Genetec and Supermax in August. Supermax is the biggest loser in my portfolio in Dec20 with a 34% decline in a month. Perhaps the only way for Supermax share price to go up is to diversify and acquire significant stake in growing tech company with its abundant cash (just kidding). Lastly, Daya just announced its PN17 regularisation plan in which a new company will take over its subsidiaries. “In my opinion, betting against stocks over the next year and beyond is betting against medicine, science and policy makers,” he said.